There is no significant difference in the primary effectiveness or safety between enteric-coated aspirin and uncoated aspirin among patients with cardiovascular disease.
There is no decrease in efficacy but no significant benefit of enteric-coated aspirin over uncoated aspirin in patients with cardiovascular disease, post hoc results of the ADAPTABLE trial suggest.